Science & Technology
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA297994-01
Award Ceiling
$1000K
Award Floor
$1000K
Close Date
Dec 31, 2026
291 days leftTotal Funding
$1000K
Expected Awards
1
Posted Date
Jan 13, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA297994-01
Description
SBIR Phase Phase II award: "Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy" awarded to Linnaeus Therapeutics Inc in HADDONFIELD, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $999,960. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.